Chlorite Formulation pH and Impurity Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing chlorite formulations are not well-suited for administration to physiological systems due to high toxicity and the presence of impurities like chlorate and sulfate ions, which can cause adverse reactions and toxicity issues.
Innovation Solution
Development of an aqueous formulation with a higher weight ratio of chlorite to chlorate or sulfate, adjusted to a pH between 7.0 and 11.5 using a pH-adjusting agent like monosodium phosphate, resulting in a formulation that is substantially free of chlorate or sulfate ions and has reduced non-specific toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional chlorite formulations (e.g., WF10, TCDO) are used, then chlorite delivery is achieved, but high levels of chlorate and sulfate impurities cause toxicity and adverse reactions
Solution Approach 1:
The patent applies extraction by removing harmful impurities (chlorate and sulfate ions) from the chlorite formulation through purification processes. The formulation is designed to contain chlorite with minimal or no chlorate and sulfate, effectively extracting the harmful components while retaining the therapeutic chlorite substance.
Solution Approach 2:
The patent changes the compositional parameters of the formulation by establishing specific ratio requirements: chlorite:chlorate weight ratio greater than 100:1.5 and chlorite:sulfate weight ratio greater than 100:16.4. These parameter changes ensure the formulation delivers effective chlorite concentrations while limiting impurity levels to non-toxic ranges.
2Stability of the object's composition
If pH is adjusted to stabilize chlorite, then formulation stability is improved, but high pH (e.g., pH 12.3 in WF10) causes tissue damage and discomfort at injection sites
Solution Approach 1:
The patent changes the pH parameter from conventional high values (pH 12.3) to an optimized range of pH 7.0-11.5, with preference for pH 7.0-9.0. This parameter change maintains chlorite stability while reducing the harmful alkaline effects on tissues, achieving a balance between formulation stability and biocompatibility.
3Reliability
If existing chlorite formulations are administered systemically, then therapeutic effects are achieved, but adverse reactions including injection site pain, asthenia, and organ damage occur
Solution Approach 1:
The patent converts the harmful high-pH property into a benefit by demonstrating that optimized pH (7.0-11.5) ranges actually improve therapeutic outcomes while eliminating adverse reactions. The formulation transforms the previously harmful alkaline nature into a controlled parameter that enhances both safety and efficacy.
Solution Approach 2:
The patent applies multiple parameter changes simultaneously: optimizing pH to 7.0-11.5, establishing chlorite:chlorate weight ratio >100:1.5, and establishing chlorite:sulfate weight ratio >100:16.4. These coordinated parameter changes transform the formulation from harmful to beneficial, achieving reliable therapeutic effects without adverse reactions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new formulation demonstrates diminished toxicity and improved safety for systemic administration, reducing adverse reactions such as injection site pain and asthenia compared to previous chlorite formulations like WF10.
Implementation Method 1
the pH adjusted using sodium hydroxide
Implementation Method 2
The purified chlorite is then dissolved in an aqueous solvent, such as water
Data Source
AI summary
Described herein are chlorite formulations having a pH between about 7 and about 8.5, wherein the chlorite formulations are substantially free of deleterious non-chlorite components. Described herein are chlorite formulations, including pharmaceutical formulations, which are formulated for systemic, parenteral, or intravenous administration. Described herein are methods of preparing and methods of using the chlorite formulations described herein.